Free tool
FAERS Monitor: Filsuvez
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215064 or its brand name (Filsuvez, Birch Triterpenes). Reports on generic versions are filed under their own applications.
Reports
276
Serious
54
20% of reports
Hospitalization
26
Death reported
13
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- wound complication43
- wound41
- product dose omission issue40
- product use issue38
- wrong technique in product usage process26
- drug ineffective25
- off label use24
- product administration interrupted24
- treatment noncompliance18
- blister17
- pruritus15
- wound secretion15
- wound infection14
- product complaint13
- impaired healing12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 53 |
| 2025 | 102 |
| 2026 | 121 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,883 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wound complicationSignal | 43 | 967.0 | 733.3 | 40,035 |
| wound secretionSignal | 15 | 293.0 | 179.0 | 4,063 |
| product administration interruptedSignal | 24 | 233.7 | 159.4 | 5,317 |
| woundSignal | 41 | 111.9 | 84.4 | 4,397 |
| wound infectionSignal | 14 | 97.6 | 58.5 | 1,242 |
| product complaintSignal | 13 | 39.1 | 23.0 | 446 |
| impaired healingSignal | 12 | 27.9 | 16.0 | 285 |
| treatment noncomplianceSignal | 18 | 25.1 | 16.0 | 393 |
| blisterSignal | 17 | 23.1 | 14.6 | 338 |
| product use issueSignal | 38 | 15.4 | 11.5 | 502 |
| product dose omission issueSignal | 40 | 10.4 | 7.8 | 334 |
| wrong technique in product usage processSignal | 26 | 9.8 | 6.8 | 198 |
| pruritusSignal | 15 | 3.0 | 1.8 | 18 |
| off label useSignal | 24 | 2.1 | 1.4 | 13 |
| drug ineffective | 25 | 1.4 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.